USWM, LLC (dba US WorldMeds)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, USWM, LLC (dba US WorldMeds) sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
USWM, LLC (dba US WorldMeds): 16 sponsored US clinical trials, none currently recruiting.
USWM, LLC (dba US WorldMeds) sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 2 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Normal Healthy Volunteers, with 1 trials.
Top-decile sponsor footprint
USWM, LLC (dba US WorldMeds) ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
NCT05993299
A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution
NCT04188730
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
NCT04070157
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
NCT02801357
Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers
NCT02681198
Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects
NCT02446002
Open-Label, Safety Study of Lofexidine
NCT02363998
Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects
NCT02313103
Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects
NCT02318836
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
NCT01863186
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
NCT01820442
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
NCT01650649
Lofexidine Mass Balance in Volunteers
NCT01629446
Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
NCT01558934
Lofexidine Food Effect Study in Healthy Volunteers
NCT01437306
Lofexidine ADME & Mass Balance in Volunteers
NCT01310296
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
How the USWM, LLC (dba US WorldMeds) early-phase archive is shaped
16 indexed studies, none listed as recruiting (0% open); 14 completed (88%).
Phase mix: 2 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Normal Healthy Volunteers (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
USWM, LLC (dba US WorldMeds): archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
USWM, LLC (dba US WorldMeds) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this USWM, LLC (dba US WorldMeds) page
16 registered trials is a research-attention snapshot, not an endorsement of USWM, LLC (dba US WorldMeds) or any single study.
- None of USWM, LLC (dba US WorldMeds)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Normal Healthy Volunteers is the condition USWM, LLC (dba US WorldMeds) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Normal Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
USWM, LLC (dba US WorldMeds) pipeline card: 16 registered trials from official public datasets.Report a data error.